Details for Patent: 10,961,190
✉ Email this page to a colleague
Which drugs does patent 10,961,190 protect, and when does it expire?
Patent 10,961,190 protects XERAVA and is included in one NDA.
This patent has nine patent family members in eight countries.
Summary for Patent: 10,961,190
| Title: | Crystalline forms of eravacycline |
| Abstract: | The invention relates to crystalline forms of the bis-HCI salt of a compound represented by Structural Formula 1, and pharmaceutical compositions comprising crystalline forms of the bis-HCL salt of a compound represented by Structural Formula 1 described herein. The crystalline forms of the bis-HCl salt of a compound of Structural Formula 1 and compositions comprising the crystalline forms of the compound of Structural Formula 1 provided herein, in particular, crystalline Form I, crystalline Form J, crystalline Form A, and crystalline Form B, or mixtures thereof, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders. Also described herein are methods for preparing the crystalline forms (e.g., Forms I, J, B and A) of the bis-HCI salt of a compound represented by Structural Formula 1. ##STR00001## |
| Inventor(s): | LaFrance; Danny (Natick, MA), Hogan; Philip C. (Brighton, MA), Liu; Yansheng (Winchester, MA), He; Minsheng (Andover, MA), Chen; Chi-Li (Newton, MA), Niu; John (Bedford, MA) |
| Assignee: | Tetraphase Pharmaceuticals, Inc. (Watertown, MA) |
| Application Number: | 16/342,779 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; |
Drugs Protected by US Patent 10,961,190
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tetraphase Pharms | XERAVA | eravacycline dihydrochloride | POWDER;INTRAVENOUS | 211109-001 | Aug 27, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Tetraphase Pharms | XERAVA | eravacycline dihydrochloride | POWDER;INTRAVENOUS | 211109-002 | Jun 3, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,961,190
| PCT Information | |||
| PCT Filed | October 19, 2017 | PCT Application Number: | PCT/US2017/057385 |
| PCT Publication Date: | April 26, 2018 | PCT Publication Number: | WO2018/075767 |
International Family Members for US Patent 10,961,190
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| China | 110582486 | ⤷ Try a Trial | |||
| European Patent Office | 3529236 | ⤷ Try a Trial | |||
| Japan | 2019531321 | ⤷ Try a Trial | |||
| Japan | 2022186979 | ⤷ Try a Trial | |||
| South Korea | 20190065414 | ⤷ Try a Trial | |||
| Morocco | 46567 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
